| 9/7/2022 |
|--|
| Meridith Balbach |
| Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| [Click or tap here to enter text.] |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial planning | g of the work |
| 1 | All support for the present | [⊠] None | |
| | manuscript | | |
| | (e.g., funding, provision of | | Click the tab key to add additional rows. |
| | study materials, medical writing, article processing charges, etc.) No time limit for this item. | | |
| | | Time frame: past 36 mont | hs |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | [⊠] None | |

| | | Name all entities with whom you have thi relationship or indicate none (add rows as needed) | paym | ifications/Comments (e.g., if nents were made to you or to your cution) |
|---|---|---|------|---|
| 3 | Royalties or licenses | None | | |
| 4 | Consulting fees | None | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | | |
| 6 | Payment for expert testimony | [⊠] None | | |
| 7 | Support for attending meetings and/or travel | [⊠] None | | |
| 8 | Patents planned, issued or pending | [⊠] None | | |
| 9 | Participation on a Data Safety | [⊠] None | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|-----|---|--|---|--|
| | Monitoring Board or Advisory Board | | | |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | [⊠] None | | |
| 1 1 | Stock or stock options | [⊠] None | | |
| 1 2 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | [⊠] None | | |
| 1 3 | Other financial or non- financial interests | [⊠] None | | |
| Ple | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

3 12/13/2021 ICMJE Disclosure Form

| Date: | 9/8/2022 |
|-------------------------------|--|
| Your Name: | Margaret L Axelrod |
| Manuscript Title: | Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| Manuscript Number (if known): | Click or tap here to enter text. |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial planning | g of the work |
| 1 | All support for the present | [⊠] None | |
| | manuscript | | |
| | (e.g., funding, provision of | | Click the tab key to add additional rows. |
| | study materials, medical writing, article processing charges, etc.) No time limit for this item. | | |
| | | Time frame: past 36 mont | hs |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | [⊠] None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | | fications/Comments (e.g., if ents were made to you or to your ution) |
|---|--|---|-----------|--|
| 3 | Royalties or licenses | None Non | | |
| 4 | Consulting fees | None None | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | | |
| 6 | Payment for expert testimony | [⊠] None | | |
| 7 | Support for attending meetings and/or travel | [⊠] None | | |
| 8 | Patents planned, issued or pending | ML Axelrod is listed as a coinventor on a provisional patent application methods to predict therapeutic outcomes using blood-based gene expression patterns, that is owned Vanderbilt University Medical Cent and is currently unlicensed. | for by | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
|-----|--|--|---|--|--|
| | | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | [⊠] None | | | |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | [⊠] None | | | |
| 1 1 | Stock or stock options | [⊠] None | | | |
| 1 2 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | [⊠] None | | | |
| 1 3 | Other financial or non- financial interests | [⊠] None | | | |
| Ple | Please place an "X" next to the following statement to indicate your agreement: | | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| I certify that I have answered every question and have not altered the wording of any of the questions \square this form. | | | ed the wording of any of the questions on |

| Date: | _9/7/2022 | |
|---------|-------------|--|
| Your Na | me: | Justin M Balko |
| Manusc | ript Title: | Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| Manusc | ript numb | er (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|---------------------------|----------------------------|---|
| | | whom you have this | (e.g., if payments were made to you or to |
| | | relationship or | your institution) |
| | | indicate none (add | |
| | | rows as needed) | |
| | Tin | ne frame: Since the initia | l planning of the work |
| 1 | All support for the | _xNone | |
| | present manuscript | | |
| | (e.g., funding, provision | | |
| | of study materials, | | |
| | medical writing, article | | |
| | processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | item. | | |
| | | Time frame: past | : 36 months |
| 2 | Grants or contracts | Genentech/Roche | |
| | from any entity (if not | Bristol Myers Squibb | |
| | indicated in item #1 | Incyte Corporation | |
| | above). | | |
| 3 | Royalties or licenses | xNone | |

| 4 | Consulting fees | _Novartis | |
|-----|---|-----------|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _xNone | |
| 6 | Payment for expert testimony | xNone | |
| 7 | Support for attending meetings and/or travel | _xNone | |
| 8 | Patents planned, issued or pending | | inventor on unlicensed patents regarding immunotherapy targets and biomarkers in cancer |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _xNone | |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone | |
| 1 | Stock or stock options | _xNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone | |
| 3 | Other financial or non- financial interests | xNone | |

| Justin Balko receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Cor received consulting/expert witness fees from Novartis, and is an inventor on patents regarding imm targets and biomarkers in cancer. | |
|--|--|
| | |

Please summarize the above conflict of interest in the following box:

| Date:9/14/20 | 22 |
|--------------------------|--|
| Your Name: | _ Armand Bankhead |
| Manuscript Title: | Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| Manuscript num | per (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | T | |
|---|---------------------------|----------------------------|---|
| | | Name all entities with | Specifications/Comments |
| | | whom you have this | (e.g., if payments were made to you or to |
| | | relationship or | your institution) |
| | | indicate none (add | your motitudion; |
| | | • | |
| | | rows as needed) | |
| | Tin | ne frame: Since the initia | I planning of the work |
| 1 | All support for the | Resolution | |
| | present manuscript | Bioscience, a part of | |
| | (e.g., funding, provision | Agilent | |
| | of study materials, | | |
| | medical writing, article | | |
| | processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | item. | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts | x None | |
| | from any entity (if not | | |
| | indicated in item #1 | | |
| | above). | | |

| 3 | Royalties or licenses | xNone | |
|----|---|--------|--|
| | | | |
| 4 | Consulting fees | xNone | |
| | | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational | _xNone | |
| | events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| 7 | Support for attending | x None | |
| , | meetings and/or travel | | |
| | , | | |
| | | | |
| 8 | Patents planned, issued | x None | |
| | or pending | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring | _xNone | |
| | Board or Advisory | | |
| | Board | | |
| 1 | Leadership or fiduciary | xNone | |
| 0 | role in other board, | | |
| | society, committee or advocacy group, paid | | |
| | or unpaid | | |
| 1 | Stock or stock options | _xNone | |
| 1 | | | |
| 12 | | | |
| 12 | Receipt of equipment, materials, drugs, | _xNone | |
| | medical writing, gifts or other services | | |
| 1 | Other financial or non- | x None | |
| 3 | financial interests | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| Date:9/14/2022 |
|---|
| Your Name:Tristan Shaffer |
| Manuscript Title:_ Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| Manuscrint number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|---------------------------|------------------------------------|---|
| | | whom you have this relationship or | (e.g., if payments were made to you or to your institution) |
| | | indicate none (add | your maticulony |
| | | rows as needed) | |
| | Tim | ne frame: Since the initia | l planning of the work |
| 1 | All support for the | Resolution | previous employer at time of work |
| | present manuscript | Bioscience, a part of | contributing to this manuscript |
| | (e.g., funding, provision | Agilent | |
| | of study materials, | | |
| | medical writing, article | | |
| | processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | item. | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts | x None | |
| | from any entity (if not | | |
| | indicated in item #1 | | |
| | above). | | |

| 3 | Royalties or licenses | xNone |
|-----|--|--------|
| | | |
| 4 | Consulting fees | xNone |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _xNone |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | _xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _xNone |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 1 | Stock or stock options | _xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 1 3 | Other financial or non- financial interests | xNone |

| Former empoloyee of Resolution Bioscience | |
|---|--|
| | |
| | |
| | |
| | |

Please summarize the above conflict of interest in the following box:

| Date: | _9/14/2022 |
|---------|--|
| Your Na | ame: Lee Lim |
| Manuso | cript Title:_ Peripheral T-cell receptor repertoire dynamics in small cell lung cancer |
| Manuso | cript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|---------------------------|----------------------------|---|
| | | whom you have this | (e.g., if payments were made to you or to |
| | | relationship or | your institution) |
| | | indicate none (add | your mondation, |
| | | • | |
| | | rows as needed) | |
| | Tim | ne frame: Since the initia | planning of the work |
| 1 | All support for the | Resolution | |
| | present manuscript | Bioscience, a part of | |
| | (e.g., funding, provision | Agilent | |
| | of study materials, | | |
| | medical writing, article | | |
| | processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | item. | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts | x None | |
| | from any entity (if not | | |
| | indicated in item #1 | | |
| | above). | | |

| 3 | Royalties or licenses | xNone |
|-----|---|--------|
| | | |
| 4 | Consulting fees | xNone |
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _xNone |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | _xNone |
| 8 | Patents planned, issued or pending | x None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _xNone |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 1 | Stock or stock options | _xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 3 | Other financial or non- financial interests | xNone |

| Current employee of Resolution Bioscience, a part of Agilent | | |
|--|--|--|
| | | |
| | | |
| | | |
| | | |

Please summarize the above conflict of interest in the following box:

| Date: 9/9/22 | |
|--|--|
| Your Name:Jiannan Guo | |
| Manuscript Title: Peripheral T-cell receptor repertoire dynamics in small cell lung cancer | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|---|---|---|
| | | whom you have this relationship or indicate none (add rows as needed) | (e.g., if payments were made to you or to your institution) |
| | Tin | ne frame: Since the initia | l planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Resolution Bioscience, a part of Agilent | Current employee |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |

| 3 | Royalties or licenses | None |
|-----|--|------|
| 4 | Consulting fees | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 1 0 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 1 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 1 3 | Other financial or non- financial interests | None |

| Current employee of Resolution Bioscience, a part of Agilent | | |
|--|--|--|
| | | |
| | | |
| | | |

Please summarize the above conflict of interest in the following box:

| Date: 9/9/22 | | |
|-------------------------|--|---|
| /our Name: Jenni | fer Hernandez | |
| Manuscript Title: | Peripheral T-cell receptor repertoire dynamics in small cell lung cancer | _ |
| Manuscript number | (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|---------------------------|----------------------------|---|
| | | whom you have this | (e.g., if payments were made to you or to |
| | | relationship or | your institution) |
| | | indicate none (add | your moneum |
| | | • | |
| | | rows as needed) | |
| | Tim | ne frame: Since the initia | l planning of the work |
| 1 | All support for the | Resolution | Current employee |
| | present manuscript | Bioscience | |
| | (e.g., funding, provision | | |
| | of study materials, | | |
| | medical writing, article | | |
| | processing charges, | | |
| | etc.) | | |
| | No time limit for this | | |
| | item. | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts | None | |
| | from any entity (if not | | |
| | indicated in item #1 | | |
| | above). | | |
| 3 | Royalties or licenses | None | |

| 4 | Consulting fees | None | |
|----|--|-------|---|
| | | | |
| | | | |
| 5 | Payment or honoraria | None | |
| | for lectures, | | |
| | presentations, speakers | | |
| | bureaus, manuscript writing or educational | | |
| | events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | _ |
| 7 | Support for attending | None | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued | None | |
| | or pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory | | |
| | Board | | |
| 1 | Leadership or fiduciary | None | |
| 0 | role in other board, | | |
| | society, committee or | | |
| | advocacy group, paid | | |
| | or unpaid | | |
| 1 | Stock or stock options | None | |
| 1 | | | |
| 12 | Receipt of equipment, | None | |
| 12 | materials, drugs, | NOTIC | |
| | medical writing, gifts or | | |
| | other services | | |
| 1 | Other financial or non- | None | |
| 3 | financial interests | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| Current employed by Resolution Bioscience | | |
|---|--|--|
| | | |
| | | |
| | | |
| | | |

| Date:9/14/22 | |
|--|--|
| Your Name:Mark Li | |
| Manuscript Title: Peripheral T-cell receptor repertoire dynamics in small cell lung cancer | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| Name all entities with Specifications/Comments | |
|--|--|
| whom you have this (e.g., if payments were made to you or to | |
| relationship or your institution) | |
| indicate none (add | |
| · | |
| rows as needed) | |
| Time frame: Since the initial planning of the work | |
| Resolution | |
| t Bioscience, a part of | |
| rision Agilent | |
| | |
| ticle | |
| | |
| , <u> </u> | |
| his | |
| | |
| | |
| | |
| Time frame: past 36 months | |
| SNone | |
| not | |
| 1 | |
| | |
| Time frame: past 36 months None None | |

| 3 | Royalties or licenses | None | |
|----|--|------|--|
| | | | |
| 4 | Consulting fees | None | |
| | | | |
| 5 | Payment or honoraria | None | |
| | for lectures, | | |
| | presentations, speakers | | |
| | bureaus, manuscript writing or educational | | |
| | events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued | None | |
| | or pending | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring | | |
| | Board or Advisory | | |
| 1 | Board Leadership or fiduciary | None | |
| 0 | role in other board, | None | |
| | society, committee or | | |
| | advocacy group, paid or unpaid | | |
| 1 | Stock or stock options | None | |
| 1 | ' | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, | None | |
| | medical writing, gifts or | | |
| | other services | | |
| 1 | Other financial or non- | None | |
| 3 | financial interests | | |
| | | | |

| President and CEO of Resolution Bioscience, a part of Agilent | | | |
|---|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| Date:9/7/22 | |
|--|--|
| Your Name:Wade T lams | |
| Manuscript Title: Peripheral T-cell receptor repertoire dynamics in small cell lung cancer | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | Tim | ne frame: Since the initia | l planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | NCCN Young Investigator Award | |
| | Time frame: past 36 months | | |
| 2 | Grants or contracts from any entity (if not | NIH Loan Repayment Award | Ongoing |
| | indicated in item #1 above). | ASCO Young Investigator Award | Past award |

| | | 2K12CA090625-17 | Past award |
|---|-------------------------|-----------------------|------------|
| 3 | Royalties or licenses | xNone | |
| | | | |
| | | | |
| 4 | Consulting fees | Genentech | |
| | | Jazz Pharma | |
| | | G1 Therapeutics | |
| | | Mirati | |
| | | Takeda | |
| | | Janssen | |
| | | Amgen | |
| | | Bristol Myers Squibb | |
| | | OncLive | |
| | | Clinical Care Options | |
| | | Chardan | |
| | | Outcomes Insights | |
| | | Cello Health | |
| | | Curio Science | |
| | | Biodesix | |
| | | | |
| | | | |
| 5 | Payment or honoraria | _xNone | |
| | for lectures, | | |
| | presentations, speakers | | |
| | bureaus, manuscript | | |
| | writing or educational | | |
| | events | NI | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| | | | |
| 7 | Support for attending | _xNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued | xNone | |
| | or pending | | |
| | | | |
| 9 | Participation on a Data | x None | |
| | Safety Monitoring | | |
| | Board or Advisory | | |
| | Board | | |
| 1 | Leadership or fiduciary | _xNone | |
| 0 | role in other board, | | |

| | society, committee or advocacy group, paid or unpaid | | |
|-----|---|--------|--|
| 1 | Stock or stock options | _xNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone | |
| 1 3 | Other financial or non- financial interests | _xNone | |

Please summarize the above conflict of interest in the following box:

WT lams has served as a consultant for Bristol Myers Squibb, OncLive, Clinical Care Options, Chardan, Outcomes
Insights, Cello Health, and Curio Science. He reports advisory board participation for Genentech, Jazz Pharma, G1
Therapeutics, Mirati, and Takeda.

Please place an "X" next to the following statement to indicate your agreement: